Shots:

• Novartis to acquire all of the outstanding shares of Gyroscope for $800M up front along with ~$700M as a milestone. Gyroscope also has multiple additional assets in its pipeline for retinal diseases
• The acquisition complements Novartis’s expertise in retinal diseases and gene therapy with the addition of GT005 in Novartis’s portfolio to develop ocular gene therapy for GA. This acquisition also builds in ophthalmology and optogenetics, following acquisitions of Vedere Bio and Arctos Medical
• GT005 is AAV2-based gene therapy for GA & is currently being evaluated in a P-I/II clinical trial and two P-II clinical trials. The therapy has received FTD from the US FDA for the treatment of GA

Ref: Novartis | Image: Novartis